Progenity to Report Third Quarter 2021 Financial Results and Provide Corporate Update
03 nov. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), an innovative biotechnology company, today announced that it will report third quarter 2021 financial results on...
Progenity Reduces Outstanding Debt by $20.175 Million Through a Private Exchange of $20.175 Million of Its 7.25% Convertible Senior Notes Due 2025 for Shares of Common Stock
26 oct. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into privately negotiated...
Progenity to Participate in Crohn’s & Colitis Foundation’s Fourth Annual IBD Innovate Conference
19 oct. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the fourth annual IBD Innovate...
Progenity Announces Several Patents Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Ingestible Therapeutics Technologies
13 oct. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
Progenity Announces Closing of $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
06 oct. 2021 16h02 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced registered...
Progenity Announces $20 Million Registered Direct Offering of Common Stock Priced at Premium to Market Under Nasdaq Rules
04 oct. 2021 13h40 HE
|
Progenity, Inc.
SAN DIEGO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced that it has entered into a definitive agreement with...
Progenity to Participate in 11th Annual Partnership Opportunities in Drug Delivery Conference
21 sept. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the company will participate in the 11th annual Partnership...
Progenity Announces Patent Granted by USPTO for its Preeclampsia Rule-Out Test
14 sept. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, announced today that the United States Patent and Trademark Office (USPTO) has...
Progenity to Participate in Two Upcoming Investor Conferences
03 sept. 2021 07h30 HE
|
Progenity, Inc.
SAN DIEGO, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced that the company will participate in two upcoming virtual investor...
Progenity Announces Closing of $40 Million Underwritten Public Offering
24 août 2021 16h05 HE
|
Progenity, Inc.
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the closing of its previously announced underwritten...